Genomic expression assay testing among American Indian and Alaska Native women with breast cancer.
Adult
Aged
Alaskan Natives
/ genetics
Biomarkers, Tumor
/ genetics
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
/ methods
Female
Gene Expression Profiling
/ methods
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Indians, North American
/ genetics
Logistic Models
Middle Aged
Practice Guidelines as Topic
SEER Program
Survival Analysis
Treatment Outcome
Young Adult
21-gene recurrence score
Alaska Native
American Indian
breast cancer
genomic expression assays
racial disparities
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 12 2020
15 12 2020
Historique:
received:
03
03
2020
revised:
02
07
2020
accepted:
20
07
2020
pubmed:
15
9
2020
medline:
21
5
2021
entrez:
14
9
2020
Statut:
ppublish
Résumé
Breast cancer is one of the most common causes of cancer mortality for all women, including American Indian and Alaska Native (AI/AN) women. The use of the 21-gene recurrence score (RS) appears to be predictive of the benefit of chemotherapy for women with estrogen receptor (ER)-positive breast cancer. The objective of the current study was to compare RS testing between AI/AN and non-Hispanic White (NHW) women with breast cancer. The Surveillance, Epidemiology, and End Results program was used to identify women with ER-positive breast cancer from 2004 through 2015. Multivariable logistic regression was used to evaluate factors associated with RS use, with high-risk RS, and with chemotherapy use among those with a high-risk RS. A total of 363,387 NHW patients and 1951 AI/AN patients with ER-positive breast cancer were identified. AI/AN women were found to be less likely to undergo RS testing and, when tested, were more likely to have a high-risk RS. In the multivariable logistic regression analysis, AI/AN women were found to be significantly more likely to have a high-risk RS (odds ratio,1.28; 95% confidence interval, 1.01-1.66). Among untested women, chemotherapy use was higher for AI/AN women; however, the use of chemotherapy was not found to be significantly different between the groups with a high-risk RS. Using Cox proportional hazards models, AI/AN race was found to be significantly associated with worse overall survival. AI/AN women were less likely to undergo RS testing compared with NHW women and were more likely to have a high-risk RS. Reversing the disparity in genomic expression assay testing is critical to ensure guideline-based breast cancer treatment and improve survival rates for AI/AN women with breast cancer.
Sections du résumé
BACKGROUND
Breast cancer is one of the most common causes of cancer mortality for all women, including American Indian and Alaska Native (AI/AN) women. The use of the 21-gene recurrence score (RS) appears to be predictive of the benefit of chemotherapy for women with estrogen receptor (ER)-positive breast cancer. The objective of the current study was to compare RS testing between AI/AN and non-Hispanic White (NHW) women with breast cancer.
METHODS
The Surveillance, Epidemiology, and End Results program was used to identify women with ER-positive breast cancer from 2004 through 2015. Multivariable logistic regression was used to evaluate factors associated with RS use, with high-risk RS, and with chemotherapy use among those with a high-risk RS.
RESULTS
A total of 363,387 NHW patients and 1951 AI/AN patients with ER-positive breast cancer were identified. AI/AN women were found to be less likely to undergo RS testing and, when tested, were more likely to have a high-risk RS. In the multivariable logistic regression analysis, AI/AN women were found to be significantly more likely to have a high-risk RS (odds ratio,1.28; 95% confidence interval, 1.01-1.66). Among untested women, chemotherapy use was higher for AI/AN women; however, the use of chemotherapy was not found to be significantly different between the groups with a high-risk RS. Using Cox proportional hazards models, AI/AN race was found to be significantly associated with worse overall survival.
CONCLUSIONS
AI/AN women were less likely to undergo RS testing compared with NHW women and were more likely to have a high-risk RS. Reversing the disparity in genomic expression assay testing is critical to ensure guideline-based breast cancer treatment and improve survival rates for AI/AN women with breast cancer.
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5222-5229Informations de copyright
© 2020 American Cancer Society.
Références
Sancar F, Abbasi J, Bucher K. Mortality among American Indians and Alaska Natives. JAMA. 2018;319:112.
White A, Richardson LC, Li C, Ekwueme DU, Kaur JS. Breast cancer mortality among American Indian and Alaska Native women, 1990-2009 [published correction appears in Am J Public Health. 2014;104:e6]. Am J Public Health. 2014;104(suppl 3):S432-S438.
Wingo PA, King J, Swan J, et al. Breast cancer incidence among American Indian and Alaska Native women: US, 1999-2004. Cancer. 2008;113(5 suppl):1191-1202.
Chen L, Li CI. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status. Cancer Epidemiol Biomarkers Prev. 2015;24:1666-1672.
Javid SH, Varghese TK, Morris AM, et al; Collaborative to Improve Native Cancer Outcomes (CINCO). Guideline-concordant cancer care and survival among American Indian/Alaskan Native patients. Cancer. 2014;120:2183-2190.
Epstein S, Tran BN, Cohen JB, Lin SJ, Singhal D, Lee BT. Racial disparities in postmastectomy breast reconstruction: national trends in utilization from 2005 to 2014. Cancer. 2018;124:2774-2784.
Emerson MA, Banegas MP, Chawla N, et al. Disparities in prostate, lung, breast, and colorectal cancer survival and comorbidity status among urban American Indians and Alaskan Natives. Cancer Res. 2017;77:6770-6777.
Burnett-Hartman AN, Adams SV, Bansal A, et al. Indian Health Service Care System and cancer stage in American Indians and Alaska Natives. J Health Care Poor Underserved. 2018;29:245-252.
Goodwin EA, Burhansstipanov L, Dignan M, Jones KL, Kaur JS. The experience of treatment barriers and their influence on quality of life in American Indian/Alaska Native breast cancer survivors. Cancer. 2017;123:861-868.
Nash SH, Meisner ALW, Zimpelman GL, Barry M, Wiggins CL. Cancer survival among Alaska Native people. Cancer. 2018;124:2570-2577.
Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
National Comprehensive Cancer Network. NCCN guidelines. Accessed February 26, 2020. https://www.nccn.org/professionals/physician_gls/default.aspx
Press DJ, Ibraheem A, Dolan ME, Goss KH, Conzen S, Huo D. Racial disparities in omission of oncotype DX but no racial disparities in chemotherapy receipt following completed oncotype DX test results. Breast Cancer Res Treat. 2018;168:207-220.
Lund MJ, Mosunjac M, Davis KM, et al. 21-Gene recurrence scores: racial differences in testing, scores, treatment, and outcome. Cancer. 2012;118:788-796.
Kizy S, Huang JL, Marmor S, Tuttle TM, Hui JYC. Impact of the 21-gene recurrence score on outcome in patients with invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2017;165:757-763.
Surveillance, Epidemiology, and End Results (SEER) Program. Research Data (1973-2015). National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2018.
Layne TM, Ferrucci LM, Jones BA, Smith T, Gonsalves L, Cartmel B. Concordance of cancer registry and self-reported race, ethnicity, and cancer type: a report from the American Cancer Society's studies of cancer survivors. Cancer Causes Control. 2019;30:21-29.
Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110:2119-2152.
Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111-121.
Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826.
Collin LJ, Yan M, Jiang R, et al. Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia. NPJ Breast Cancer. 2019;5:32.
Andre F, Ismaila N, Henry NL, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: ASCO Clinical Practice Guideline Update-integration of results from TAILORx. J Clin Oncol. 2019;37:1956-1964.
Wilson RT, Giroux J, Kasicky KR, et al. Breast and cervical cancer screening patterns among American Indian women at IHS clinics in Montana and Wyoming. Public Health Rep. 2011;126:806-815.
Cunningham PJ, Cornelius LJ. Access to ambulatory care for American Indians and Alaska Natives; the relative importance of personal and community resources. Soc Sci Med. 1995;40:393-407.
Wilson RT, Adams-Cameron M, Burhansstipanov L, et al. Disparities in breast cancer treatment among American Indian, Hispanic and Non-Hispanic white women enrolled in Medicare. J Health Care Poor Underserved. 2007;18:648-664.
Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with Medicare claims. Med Care. 2016;54:e55-e64.
Yueh B. The threshold of clinical significance. JAMA Otolaryngol Head Neck Surg. Published online December 5, 2019. doi:10.1001/jamaoto.2019.3741
Wasserstein RL, Lazar NA. The ASA statement on P values: context, process, and purpose. Am Stat. 2016:129-133. https://www.tandfonline.com/doi/full/10.1080/00031305.2016.1154108
Amrhein V, Greenland S, McShane B. Scientists rise up against statistical significance. Nature. 2019;567:305-307.